B
HLB바이오스텝
278650KOSDAQ61.0 / 100
Reference Date: 2026-10-23
Financial Score18.5 / 40
News Sentiment12.5 / 25
Momentum20.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 127.2% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
HLB Biosstep specializes in non-clinical CRO services, particularly in efficacy evaluation for pharmaceutical development, leveraging its expertise in high-complexity experiments using major animals like pigs and beagles. The company expanded its offerings in 2024 by acquiring HLB BioCode, a GLP toxicity testing specialist, and also provides animal facility construction and maintenance services.
Number of Employees
150people
Average Salary
61.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
0.99Industry Average 1.204.0Point
In line with industry avg
ROE
-18.60Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
6.60Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲18.7% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼441.2% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -9.2% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position8.0Point
Near 52w high (94%, uptrend)
Current 5,760Won52-week high 6,01052-week low 1,099
1-month return6.0Point
1m +127.22% (strong rise)
Volume trend6.0Point
Volume surge
Detailed Disclosure
2 totalPositive 0Neutral 2Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-10-13
- Neutral기업설명회(IR)개최2026-10-12